After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...